Zelnorm Surgery Incidence Halved Via Novartis/FDA Adjudication
This article was originally published in Pharmaceutical Approvals Monthly
Re-analysis of surgical cases in clinical trials for Novartis’ constipation-predominant irritable bowel syndrome therapy Zelnorm reduced the incidence of the events by more than half, FDA review documents indicate.
You may also be interested in...
Novartis’ upcoming sNDA for a Zelnorm chronic constipation indication could increase the potential patient population for the drug by roughly 50%.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011